Guo X, Wang S, Ma Y, Du Y, et al. Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study. NPJ Precis Oncol 2025 Dec 3. doi: 10.1038/s41698-025-01211.
PMID: 41331072